Canaccord is Bullish on Aurora Cannabis Inc. (ACB)

Core Insights - Aurora Cannabis Inc. (NASDAQ: ACB) is recognized as one of the best cannabis stocks to invest in currently [1][2] - Canaccord has reduced its price target for Aurora Cannabis from C$10 to C$9 while maintaining a Buy rating [2] Financial Performance - In Q3 of fiscal 2026, Aurora Cannabis reported a 7% year-over-year growth in total net sales, reaching $94.2 million [3] - Medical cannabis net sales in Germany and Poland increased by 12% to a record $76.2 million [3] - The company achieved free cash flow of $15.5 million, adjusted net income of $7.2 million, and adjusted EBITDA of $18.5 million [3] - At the end of the quarter, Aurora Cannabis announced a debt-free status with $154.4 million in cash and short-term investments [3] Business Operations - Aurora Cannabis operates through its Plant Propagation and Cannabis divisions, focusing on the production, distribution, and sale of cannabis and cannabis-derived products [4] - The management emphasizes leadership in genetics, GMP production, global medicinal cannabis, operational efficiency, regulatory knowledge, and potential M&A opportunities [3]